Current and historical daily PE Ratio for Regent Pacific Group Ltd (
HKSE:00575
) from 1997 to Apr 26 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Regent Pacific Group stock (HKSE:00575) PE ratio as of Apr 26 2024 is 0.
More Details
Regent Pacific Group Ltd (HKSE:00575) PE Ratio (TTM) Chart
Regent Pacific Group Ltd (HKSE:00575) PE Ratio (TTM) Historical Data
View and export this data going back to 1997. Start your Free Trial
Total 1195
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Regent Pacific Group PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-09 | At Loss |
| 2024-04-18 | At Loss | 2024-02-08 | At Loss |
| 2024-04-17 | At Loss | 2024-02-07 | At Loss |
| 2024-04-16 | At Loss | 2024-02-06 | At Loss |
| 2024-04-15 | At Loss | 2024-02-05 | At Loss |
| 2024-04-12 | At Loss | 2024-02-02 | At Loss |
| 2024-04-11 | At Loss | 2024-02-01 | At Loss |
| 2024-04-10 | At Loss | 2024-01-31 | At Loss |
| 2024-04-09 | At Loss | 2024-01-30 | At Loss |
| 2024-04-08 | At Loss | 2024-01-29 | At Loss |
| 2024-04-05 | At Loss | 2024-01-26 | At Loss |
| 2024-04-03 | At Loss | 2024-01-25 | At Loss |
| 2024-04-02 | At Loss | 2024-01-24 | At Loss |
| 2024-03-28 | At Loss | 2024-01-23 | At Loss |
| 2024-03-27 | At Loss | 2024-01-22 | At Loss |
| 2024-03-26 | At Loss | 2024-01-19 | At Loss |
| 2024-03-25 | At Loss | 2024-01-18 | At Loss |
| 2024-03-22 | At Loss | 2024-01-17 | At Loss |
| 2024-03-21 | At Loss | 2024-01-16 | At Loss |
| 2024-03-20 | At Loss | 2024-01-15 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
| 2024-03-15 | At Loss | 2024-01-10 | At Loss |
| 2024-03-14 | At Loss | 2024-01-09 | At Loss |
| 2024-03-13 | At Loss | 2024-01-08 | At Loss |
| 2024-03-12 | At Loss | 2024-01-05 | At Loss |
| 2024-03-11 | At Loss | 2024-01-04 | At Loss |
| 2024-03-08 | At Loss | 2024-01-03 | At Loss |
| 2024-03-07 | At Loss | 2024-01-02 | At Loss |
| 2024-03-06 | At Loss | 2023-12-29 | At Loss |
| 2024-03-05 | At Loss | 2023-12-28 | At Loss |
| 2024-03-04 | At Loss | 2023-12-27 | At Loss |
| 2024-03-01 | At Loss | 2023-12-22 | At Loss |
| 2024-02-29 | At Loss | 2023-12-21 | At Loss |
| 2024-02-28 | At Loss | 2023-12-20 | At Loss |
| 2024-02-27 | At Loss | 2023-12-19 | At Loss |
| 2024-02-26 | At Loss | 2023-12-18 | At Loss |
| 2024-02-23 | At Loss | 2023-12-15 | At Loss |
| 2024-02-22 | At Loss | 2023-12-14 | At Loss |
| 2024-02-21 | At Loss | 2023-12-13 | At Loss |
Regent Pacific Group Ltd (HKSE:00575) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Regent Pacific Group Ltd
NAICS : 212299
ISIN : KYG7478U1206
Compare
Compare
Traded in other countries / regions
00575.Hong KongRPG.GermanyRPGLF.USA IPO Date
1997-05-19Description
Regent Pacific Group Ltd Formerly Endurance RP Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers